Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.
about
Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice.IKKα/CHUK regulates extracellular matrix remodeling independent of its kinase activity to facilitate articular chondrocyte differentiation.Rhabdomyosarcoma of the head and neck in childrenNew Treatments for Rhabdomyosarcoma: the Importance of Target PracticeMicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma.CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive RhabdomyosarcomaAlveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesisImpact of malocclusion on oral health related quality of life in young people.Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.Focus on PNA Flexibility and RNA Binding using Molecular Dynamics and Metadynamics.MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.Peptide nucleic acids: a review on recent patents and technology transfer.Chemical modifications of artificial restriction DNA cutter (ARCUT) to promote its in vivo and in vitro applications.Uncovering metabolism in rhabdomyosarcoma.JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas.Fusion gene addiction: can tumours be forced to give up the habit?The MYCN Protein in Health and Disease.PNA-NLS conjugates as single-molecular activators of target sites in double-stranded DNA for site-selective scission.Genetic heterogeneity in rhabdomyosarcoma revealed by SNP array analysis.IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.Furan-PNA: a mildly inducible irreversible interstrand crosslinking system targeting single and double stranded DNA.Promotion of double-duplex invasion of peptide nucleic acids through conjugation with nuclear localization signal peptide.The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma.Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma
P2860
Q34028460-FA582D1A-B4FA-46D7-A67C-F826A13090B4Q34984184-A157D70C-6C76-433B-986C-258304B9398CQ35648994-42AAAC16-17AB-4D18-99A5-70078E22975AQ35729362-3E9A301E-899C-4CC5-B49C-7BD194BAF940Q35922940-782BE5B1-9574-4A15-A6BE-0401318DF5F9Q36093810-74A0BC4B-8961-461D-B35D-970FDE68D5FDQ36588372-30C09B45-EA24-4B38-B218-6BBF487FCEA0Q36687386-F4AAA413-A450-4FEB-9DA9-AE0ADC962EA9Q36903863-EFBB887F-A37A-4B42-AAB5-13003893F5C8Q37199465-E61E102D-38C8-419A-BBDE-A39EBB8434EEQ37281508-7A7E759B-96B0-4444-BA34-16B2D871D530Q37648615-ED62319C-023E-4D92-AF21-6D70FF14276FQ37649646-6E4E26A4-A327-466E-9414-524382DD37C8Q38083828-29C22AB7-8C90-4DFF-8F11-7AC6E62D8278Q38176989-1720DF7C-BB1E-4CA5-892D-C7A710168375Q38294445-5191C9FE-4437-4FBB-A8F6-509B6F583E2BQ38553827-F78BB593-1B5D-49F9-AD44-CAE8ABE09BE7Q38688601-30EBB8B3-1D80-4907-A647-8C80A82D6F4CQ38718679-3215BF28-2209-4FA9-932B-BD93F9C85DB3Q38725853-F5D1C86A-7553-4810-BB59-6F7775F40955Q38853922-ECA89A44-51C1-43DD-A0B4-7351ACEBBB03Q39208675-4B079C8B-B62C-418D-A9F7-0AB5AE2C8471Q39392103-812346FC-3D83-4D5A-B013-2CDF307FD2E2Q40414512-9885A5CC-EAFF-4483-AC7E-C42D1E75DB92Q48262511-84A85DB3-7776-48DF-9EDC-B095752651BFQ50856125-704A7825-558C-4AFE-85DD-A9D9FA844E1FQ51012807-5A080EA5-0B2C-434B-912C-29DFA7540119Q51749352-CBB9DBFB-922B-4735-A8E3-0901F03F202AQ54164887-FC3B8734-E094-4E03-9E9F-82D19FAE4B4BQ58702896-F6D1AF89-D7FF-4F87-B56A-110E39CB0250
P2860
Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Antitumor activity of sustaine ...... nal block by antigene therapy.
@en
Antitumor activity of sustaine ...... nal block by antigene therapy.
@nl
type
label
Antitumor activity of sustaine ...... nal block by antigene therapy.
@en
Antitumor activity of sustaine ...... nal block by antigene therapy.
@nl
prefLabel
Antitumor activity of sustaine ...... nal block by antigene therapy.
@en
Antitumor activity of sustaine ...... nal block by antigene therapy.
@nl
P2093
P50
P1476
Antitumor activity of sustaine ...... nal block by antigene therapy.
@en
P2093
Andrea Faccini
Andrea Tortori
Brenda Summersgill
Consuelo Camerin
Cristina Nanni
Giorgio Cantelli-Forti
Ivo Leuschner
Jane Renshaw
Janet Shipley
Kathryn R Taylor
P304
P356
10.1158/1078-0432.CCR-11-1981
P407
P50
P577
2011-11-07T00:00:00Z